Hemgenix® (etranacogene dezaparvovec-drlb)
| Full Name | Hemgenix® (etranacogene dezaparvovec-drlb) |
| Drug | Hemgenix |
| Manufacturer | CSL Behring |
| Route of Administration | Intravenous |
| Site of Care | Healthcare Facility |
| Approved Indication | The treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes |
| Disease | Hemophilia B |
| Therapeutic Area | Hematology; Cell & Gene Therapy |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-975-8693 |
| Fax Number | 877-740-7535 |
| Product Website | hemgenix.com/hcp |